M&A Deal Summary

IBA Molecular Imaging Acquires Mallinckrodt - Nuclear Imaging Business

On August 24, 2016, IBA Molecular Imaging acquired medical products company Mallinckrodt - Nuclear Imaging Business from Mallinckrodt for 690M USD

Acquisition Highlights
  • This is IBA Molecular Imaging’s 1st transaction in the Medical Products sector.
  • This is IBA Molecular Imaging’s largest (disclosed) transaction.
  • This is IBA Molecular Imaging’s 1st transaction in Ireland.

M&A Deal Summary
Date 2016-08-24
Target Mallinckrodt - Nuclear Imaging Business
Sector Medical Products
Buyer(s) IBA Molecular Imaging
Sellers(s) Mallinckrodt
Deal Type Divestiture
Deal Value 690M USD

Target

Mallinckrodt - Nuclear Imaging Business

Dublin, Ireland
Mallinckrodt - Nuclear Imaging Business includes a portfolio of diagnostic imaging products. Nuclear Imaging business originate in the U.S. The business is a prominent global producer of the key medical isotope molybdenum-99, from which technetium-99m (Tc-99m) is derived. Tc-99m is used in roughly 80%1 of all nuclear medicine procedures worldwide.

Search 200,197 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

IBA Molecular Imaging

Dulles, Vermont, United States
Category Company
Sector Medical Products
Employees1,000
DESCRIPTION

IBA Molecular is a global developer, manufacturer and distributor of radiopharmaceutical products and supporting services used in molecular imaging. IBA Molecular has engineered a strong and unique product portfolio and pipeline of diagnostic and therapeutic tracers aimed at advancing the development of the global movement towards personalized medicine and making molecular imaging/therapy a major discipline in healthcare. The company also provides educational, technical and marketing support to medical specialists worldwide to help better respond to patient needs.

DEAL STATS #
Overall 1 of 1
Sector (Medical Products) 1 of 1
Type (Divestiture) 1 of 1
Country (Ireland) 1 of 1
Year (2016) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-04-17 Zevacor Pharma

Noblesville, Indiana, United States

Zevacor Pharma is a developer, manufacturer and distributor of PET radiopharmaceutical products and supporting services used in molecular imaging in the U.S. Zevacor has a unique product portfolio and pipeline of diagnostic tracers aimed at advancing the development of the global movement towards personalized medicine and making molecular imaging a major discipline in healthcare.

Sell -

Seller(S) 1

SELLER

Mallinckrodt

Dublin, United Kingdom
Category Company
Founded 1867
Sector Life Science
Employees2,673
Revenue 2.2B USD (2021)
DESCRIPTION

Mallinckrodt is a specialty pharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company’s core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. Mallinckrodt was founded in 1867 and is based in Dublin, Ireland.

DEAL STATS #
Overall 3 of 7
Sector (Medical Products) 2 of 4
Type (Divestiture) 3 of 7
Country (Ireland) 1 of 4
Year (2016) 1 of 1
Size (of disclosed) 2 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-08-10 Stratatech

Madison, Wisconsin, United States

Stratatech Corp. is a privately held regenerative medicine company focused on the development of unique, proprietary skin substitute products.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-01-30 Mallinckrodt - Intrathecal Therapy Business

Dublin, Ireland

Mallinckrodt plc - Intrathecal Therapy Business includes Gablofen® (baclofen), a severe spasticity management product, which is currently marketed in the United States, and two pain management products, which are currently under development.

Sell $171M
Mergr

Product

Company

Legal